Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Michael Panny
Observed name:
M. Panny
Institution:
Hanusch Hospital
Observed institutions:
Hanusch Hospital,
Medical University of Vienna
ORCID:
0000-0001-7058-3844
Observed ORCID:
0000-0001-7058-3844
OpenAlex ID:
A5042951682
Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders
2021
·
Christoph Kornauth
, Tea Pemovska
, et al.
·
Cancer Discovery
·
220
First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia
2017
·
Bernd Boidol
, Christoph Kornauth
, et al.
·
Blood
·
75
Exposure to Air Ions in Indoor Environments: Experimental Study with Healthy Adults
2015
·
Peter Wallner
, Michael Kundi
, et al.
·
International Journal of Environmental Research and Public Health
·
29
PDF
High‐dose Bendamustine‐ EAM followed by autologous stem cell rescue results in long‐term remission rates in lymphoma patients, without renal toxicity
2018
·
Thomas Noesslinger
, Michael Panny
, et al.
·
European Journal Of Haematology
·
17
Angio-Seal Use in Patients with Peripheral Arterial Disease (ASPIRE)
2009
·
Reinhold Katzenschlager
, Reinhold Tischler
, et al.
·
Angiology
·
15
Feasibility and Safety of the First-in-Human Chemotherapy-Light Combination of Rituximab, Polatuzumab Vedotin and Glofitamab in Previously Untreated Aggressive B-Cell Lymphoma Patients Above 60 Years of Age Ineligible for a Fully Dosed R-CHOP - R-Pola-Glo/Ikf-t062, a Study of the Austrian Group for Medical Tumor Therapy (AGMT-NHL-16) and the German Lymphoma Alliance (GLA2022-10)
2023
·
Thomas Melchardt
, Rebecca I Wurm-Kuczera
, et al.
·
Blood
·
14
Treatment with brentuximab vedotin plus bendamustine in unselected patients with CD30‐positive aggressive lymphomas
2019
·
Sandro M. Wagner
, Thomas Melchardt
, et al.
·
European Journal Of Haematology
·
13
PDF
The Combination of Pixantrone, Etoposide, Bendamustine and, in CD20+ Tumors, Rituximab (PREBEN) Shows Promising Feasibility/Efficacy in Heavily Pre-Treated Aggressive Lymphomas of B- and T-Cell Phenotype - Results of the Pre-Trial Experience Leading to a Nordic Phase 1/2 Study (the PREBEN Trial)
2016
·
Michael Roost Clausen
, Sirpa Leppa
, et al.
·
Blood
·
10
BendaEAM versus BEAM as conditioning regimen for ASCT in patients with relapsed lymphoma (BEB): a multicentre, randomised, phase 2 trial
2023
·
Felix Keil
, Antonia M.S. Müller
, et al.
·
EClinicalMedicine
·
8
PDF
159 | R‐pola‐glo – Chemo‐light Frontline Therapy Induces High Response Rates With a Favorable Safety Profile in Elderly/frail Patients With Aggressive Lymphoma
2025
·
R. Wurm‐Kuczera
, T. Melchardt
, et al.
·
Hematological Oncology
·
4
PDF
Autologous Stem Cell Transplantation with Benda-Eam (Bendamustine, Etoposide, Cytarabine, Melphalan) in Aggressive Non Hodgkin and Hodgkin´s Lymphoma
2016
·
Thomas Noesslinger
, Michael Panny
, et al.
·
Blood
·
3
Aggressive B cell lymphomas—highlights from ASH 2022
2023
·
Michael Panny
·
memo - Magazine of European Medical Oncology
·
2
Treatment Guided By Next Generation Functional Drug Screening Provides Clinical Benefit in Advanced Aggressive Hematological Malignancies: Final Evaluation of the Open Label, Single Arm Exalt Trial
2020
·
Christoph Kornauth
, Tea Pemovska
, et al.
·
Blood
·
2
Facial Diplegia as Initial Manifestation of Acute, Myelomonocytic Leukemia with Isolated Trisomy 47, XY,+11[14]/46, XY[6]
2017
·
Josef Finsterer
, Michael Panny
·
Journal of Neurosciences in Rural Practice
·
2
PDF
Advanced stage Hodgkinʼs lymphoma 2024—Update on first line treatment
2024
·
Barbara Lehner
, Michael Panny
·
memo - Magazine of European Medical Oncology
·
1
Hodgkin lymphoma—how much therapy do we need?
2022
·
Barbara Lehner
, Michael Panny
·
memo - Magazine of European Medical Oncology
·
1
A Randomized Phase II Trial Comparing BeEAM with BEAM As Conditioning Regimen for Autologous Stem Cell Transplantation in Lymphoma Patients
2022
·
Felix Keil
, Antonia Maria Susanne Müller
, et al.
·
Blood
·
1
ASH 2018—aggressive lymphoma
2019
·
Michael Panny
·
memo - Magazine of European Medical Oncology
·
1
Treatment of High Risk Aggressive B Cell Lymphomas with DA EPOCH R- a Retrospective Analysis
2016
·
Michael Panny
, Katharina Troppan
, et al.
·
Blood
·
1
Is more better in myeloma? Treatment intensity and outcome in newly diagnosed myeloma patients
2015
·
Michael Fillitz
, Adelheid Seebacher
, et al.
·
memo - Magazine of European Medical Oncology
·
1
Supplementary Data from Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders
2025
·
Christoph Kornauth
, Tea Pemovska
, et al.
ASH 2024—aggressive B cell lymphoma highlights
2025
·
Michael Panny
·
memo - Magazine of European Medical Oncology
Comorbidity & Cll Different Scores – Different Results
2023
·
V. Rathkolb
, T. Nösslinger
, et al.
·
Hematological Oncology
PDF
Data from Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders
2023
·
Christoph Kornauth
, Tea Pemovska
, et al.
Supplementary Data from Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders
2023
·
Christoph Kornauth
, Tea Pemovska
, et al.
Show more works
View as search
Works count:
31
Citation count:
420
H-index:
8
I10-index:
8
Year
Topic
Type
